Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation

Paul Wexberg; Nelli Jordanova; Christoph Strehblow; Bonni Syeda; Brigitte Meyer; Silvia Charvat; Gerlinde Zorn; Daniela Scheinig; Johann Wojta; Kurt Huber; Dietmar Glogar; Mariann Gyöngyösi

doi:10.1160/TH07-05-0365

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(04): 739-748
DOI: 10.1160/TH07-05-0365

Cardiovascular Biology and Cell Signalling

Schattauer GmbH

Time course of prothrombotic and proinflammatory substance release after intracoronary stent implantation

Authors

Paul Wexberg

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Nelli Jordanova

²Department of Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria
Christoph Strehblow

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Bonni Syeda

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Brigitte Meyer

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Silvia Charvat

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Gerlinde Zorn

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Daniela Scheinig

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Johann Wojta

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Kurt Huber

²Department of Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria
Dietmar Glogar

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria
Mariann Gyöngyösi

¹Department of Cardiology, Medical University of Vienna, Vienna, Austria

Abstract

Summary

We hypothesized that restenosis after coronary stenting is predicted by elevated levels of markers of thrombus formation and inflammation. Plasma levels of representative markers of inflammation, the thrombin and plasmin activation systems and adhesion molecules were measured in 59 patients with stable angina pectoris before, immediately after and 6 hours (h), 12 h, 24 h, one month and six months after elective stent implantation (radioactive phosphorus-32 stents /RSs/ n=16,bare-metal stents /BMSs/ n=43). All patients underwent clinical and angiographic follow-up (FUP) six months after stenting. RSs had significantly higher angiographic severity of restenosis than BMSs (47.1 ± 20.1% vs. 27.6 ± 22.0%, p=0.003). Repeated measures ANOVA revealed significant differences between the BMS and RS groups as regards the increases in plasma levels of vascular cell adhesion molecule-1 (VCAM-1, p=0.022), plasminogen activator inhibitor-1 (PAI-1, p=0.047), tissue-type plasminogen activator (tPA, p=0.047) and CD40 ligand (CD40L, p=0.038). tPA levels tended to increase immediately after stenting in both groups, whereas the PAI-1 level one month after stenting was elevated significantly only in the RS group. In the RS group, the plasma levels of CD40L were increased at 24 h and six months after stenting, and the VCAM-1 level rose immediately after stenting and remained high during the FUP. Multivariate analysis on pooled laboratory data of both groups revealed elevated levels of VCAM-1 at 12 h and at six months as significant predictors of the severity of stent restenosis. In conclusion, the process of inflammation and thrombosis occurring after coronary interventions seems to be prolonged and enhanced in patients with highgrade restenosis at the follow up.

Keywords

Coronary artery disease - stent - restenosis - inflammation - thrombosis

Full Text

References

References
1 Santin M, Colombo P, Bruschi G. Interfacial biology of in-stent restenosis. Expert Rev Med Devices 2005; 2: 429-443.
2 Schiele T. Current understanding of coronary instent restenosis. Pathophysiology, clinical presentation, diagnostic work-up, and management. Z Kardiol 2005; 94: 772-790.
3 Albiero R, Nishida T, Adamian M. et al. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents. Circulation 2000; 101: 2454-2457.
4 Togni A, Windecker S, Wenaweser P. et al. Deleterious effect of coronary brachytherapy on vasomotor response to exercise. Circulation 2004; 110: 135-140.
5 Wardeh A, Knook A, Kay I. et al. Clinical and angiographic follow-up after implantation of a 6-12 μCi radioactive stent in patients with coronary artery disease. Eur Heart J 2001; 22: 669-675.
6 Gottsauner-Wolf M, Zasmeta G, Hornykewycz S. et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152-1158.
7 Fischell D, Fischell T, Fischell R. et al. The Balloon eXpandable (BXTM) stent. Handbook of coronary stents.. London: Martin Dunitz Ltd; 1998: 213-220.
8 Janicki C, Duggan D, Coffey C. et al. Radiation dose from a phosphorus-32 impregnated wire mesh vascular stent. Med Phys 1997; 24: 437-445.
9 Albiero R, Adamian M, Kobayashi N. et al. Shortand intermediate-term results of 32P radioactive ß-emitting stent implantation in patients with coronary artery disease. The Milan Dose-Response Study. Circulation 2000; 101: 18-26.
10 Ryan T, Faxon D, Gunnar R. et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Tast Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Circulation 1988; 78: 486-502.
11 Popma J, Bashore T. Qualitative and quantitative angiography. Textbook of Interventional Cardiology.. Philadelphia, Pa: WB Saunders; 1994: 1052-1068.
12 Samara W, Gurbel P. The role of platelet receptors and adhesion molecules in coronary artery disease. Coronary Artery Dis 2003; 14: 65-79.
13 van der Putten R, Glatz J, Hermens W. Plasma markers of activated haemostasis in the early diagnosis of acute coronary syndromes. Clin Chim Acta 2006; 371: 37-54.
14 Kopp C, Steiner S, Priglinger U. et al. Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic drug regimen in coronary artery stenting. Blood Coagul Fibrinolysis 2003; 14: 379-386.
15 Binder B, Mihaly J, Prager G. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist’s view. Thromb Haemost 2007; 97: 336-342.
16 Gyöngyösi M, Glogar D, Weidinger F. et al. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-ST-segment elevation myocardial infarction. Am Heart J 2004; 147: 158-164.
17 Gyöngyösi M, Strehblow C, Sperker W. et al. Platelete activation and high tissue factor levels predict acute stent thrombosis in pig coronary arteries: prothrombogenic response of drug-eluting or bare stent implantation within the first 24 hours. Thromb Haemost 2006; 96: 202-209.
18 Johansson L, Jansson J, Boman K. et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000; 31: 26-32.
19 Pradhan A, La Croix A, Langer R. et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 2004; 110: 292-300.
20 Gawaz M, Neumann F, Ott I. et al. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis. Coronary Artery Dis 1997; 8: 121-128.
21 Kirschstein W, Simianer S, Dempfle C. et al. Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). Thromb Haemost 1989; 62: 772-775.
22 Mulvihill N, Foley J, Walsh M, Crean P. Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules. Int J Cardiol 2001; 77: 223-229.
23 Heider P, Wildgruber M, Weiss W. et al. Role of adhesion molecules in the induction of restenosis after angioplasty in the lower limb. J Vasc Surg 2006; 43: 969-977.
24 Kilickap M, Tutar E, Aydintug O. et al. Increase in soluble E-selectin level after PTCA and stent implantation: a potential marker of restenosis. Int J Cardiol 2004; 93: 13-18.
25 Wexberg P, Beran G, Lang I. et al. Percutaneous interventions in radiation associated coronary in-stent restenosis. Cardiovasc Intervent Rad 2003; 26: 154-157.
26 Thompson S, Kienast J, Pyke S. et al. Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
27 Jansson J, Olofsson B, Nilsson T. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993; 88: 2030-2034.
28 Huber K, Jorg M, Probst P. et al. A decrease in plasminogen activator inhibitor-1 activity after sucessful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67: 209-213.
29 Sakata K, Miura F, Sugino H. et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
30 Yang Z, Eton D, Zheng F, Livingstone A, Yu H. Effect of tissue plasminogen activator on vascular smooth muscle cells. J Vasc Surg 2005; 42: 532-538.
31 Huber K. Defective fibrinolytic states as triggers of myocardial infarction: the cardiologist’s view. Ital Heart J 2001; 2: 646-651.
32 Wexberg P, Kirisits C, Gyöngyösi M. et al. Vascular morphometric changes after radioactive stent implantation: a dose-response analysis. J Am Coll Cardiol 2002; 39: 400-407.
33 Pasterkamp G, De Kleijn D, Borst C. Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications. Cardiovasc Res 2000; 45: 843-852.
34 Glagov S, Weisenberg E, Zarins C. et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
35 Wexberg P, Gyöngyösi M, Sperker W. et al. Preexisting arterial remodeling is associated with in-hospital and late adverse cardiac events after coronary interventions in patients with stable angina pectoris. J Am Coll Cardiol 2000; 36: 1860-1869.
36 Stone G, Moses J, Ellis S. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stent. N Engl J Med 2007; 356: 998-1008.
37 Kastrati A, Mehilli J, Pache J. et al. Analysis of 14 trials comparing sirolimus-eluting stents with baremetal stents. N Engl J Med 2007; 356: 1030-1039.
38 Wiedermann J, Leavy J, Amols H. et al. Effects of High – Dose Intracoronary Irradiation on Vasomotor Function and Smooth Muscle Histopathology. Am J Physiol 1994; 267: H125-H132.
39 Li J, De Leon H, Ebato B. et al. Endovascular irradiation imparis vascular functional responses in oninjured pig coronary arteries. Cardiovasc Radiat Med 2002; 3: 152-162.
40 Gogo PJ, Schneider DJ, Watkins MW. et al. Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis 2005; 19: 87-92.
41 Kim J, Ko Y, Shim C. et al. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels. Am J Cardiol 2005; 96: 1384-1388.
42 Patti G, Chello M, Pasceri V. et al. Dexamethasoneeluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study. Clin Ther 2005; 27: 1411-1419.
43 Geppert A, Graf S, Beckmann R. et al. Concentration of endogenous tPA antigen in coronary artery disease. Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 1998; 18: 1634-1642.